DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Damora Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$19.27+0.83 (+4.50%)
Close on Oct 19, 2026
- Market cap
- $1.18B
- P/E (TTM)
- 4.8
- Dividend yield
- 0.00%
Share price
+$9.69 (+101.1%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.18B
- P/E ratio
- 4.8
- Price to sales
- –
- Price to book
- 2.28
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Net income
- -$262.83M
- EPS, diluted
- $3.98
- Book value per share
- $8.44
- Diluted shares
- 61M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
-$270.66M
Net income
-$262.83M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months